September 06, 2021
Video
Harry Webster, RPh, a registered pharmacist at Walgreens and a member of the LGBTQIA+ community, discusses the impact of stigma associated with PrEP and HIV on patients seeking to treat or prevent HIV.
September 01, 2021
Article
Collaborative efforts between patients, physicians, pharmacists, and other essential personnel can further promote the effectiveness of PrEP regimens.
August 27, 2021
Brad McElya, PharmD, director of specialty health solutions at Walgreens, discusses the critical role pharmacists play in providing HIV prevention drugs in communities across America.
August 09, 2021
Truvada is a medicine people at risk for HIV should take to prevent infection with the virus from various ways, such as sex or injection drug use.
August 06, 2021
A generic TDF/FTC costs as low as $30 per month, compared with about $1800 per month for branded TAF/FTC
April 27, 2021
Despite the fact that 98% of the survey respondents said they were aware of PrEP, less than 25% were currently taking it.
March 12, 2021
The sNDA seeks to expand the label of cabotegravir and rilipivirine to include dosing of every 2 months for the treatment of HIV-1 infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter) on a stable regimen.
March 10, 2021
New, long-term data from open-label extensions of a pair of phase 3 studies of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets showed the sustained efficacy and safety profile of the treatment.
February 25, 2021
Geographic shifts in the HIV epidemic, racial disparities, and the complexities of the medical system all present obstacles to prevention and treatment services.
February 22, 2021
Researchers, advocates, and other stakeholders are urging for care to be expanded to overcome barriers in high-risk populations to address the HIV epidemic, as part of a series published in The Lancet HIV in the USA Series.
